Literature DB >> 19407738

Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

.   

Abstract

Since April 21, 2009, CDC has reported cases of respiratory infection with a swine-origin influenza A (H1N1) virus (S-OIV) that is being spread via human-to-human transmission. As of April 28, the total number of confirmed S-OIV cases in the United States was 64; these cases occurred in California (10 cases), Kansas (two), New York (45), Ohio (one), and Texas (six). The viruses contain a unique combination of gene segments that had not been reported previously among swine or human influenza viruses in the United States or elsewhere. Viruses from 13 (20%) of 64 patients have been tested for resistance to antiviral medications. To date, all tested viruses are resistant to amantadine and rimantadine but are susceptible to oseltamivir and zanamivir. The purpose of this report is to provide detailed information on the drug susceptibility of the newly detected S-OIVs, which will aid in making recommendations for treatment and prophylaxis for swine influenza A (H1N1) infection. These data also will contribute to antiviral-resistance monitoring and diagnostic test development.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407738

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  96 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Authors:  Elena A Govorkova; Bindumadhav M Marathe; Ashley Prevost; Jerold E Rehg; Robert G Webster
Journal:  Antiviral Res       Date:  2011-05-27       Impact factor: 5.970

3.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

Review 4.  Influence of solubilizing environments on membrane protein structures.

Authors:  Timothy A Cross; Mukesh Sharma; Myunggi Yi; Huan-Xiang Zhou
Journal:  Trends Biochem Sci       Date:  2010-08-18       Impact factor: 13.807

5.  Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.

Authors:  Elodie Ghedin; Jennifer Laplante; Jay DePasse; David E Wentworth; Roberto P Santos; Martha L Lepow; Joanne Porter; Kathleen Stellrecht; Xudong Lin; Darwin Operario; Sara Griesemer; Adam Fitch; Rebecca A Halpin; Timothy B Stockwell; David J Spiro; Edward C Holmes; Kirsten St George
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

6.  Pharmacokinetics of oseltamivir according to trimester of pregnancy.

Authors:  Laura G Greer; Richard D Leff; Vanessa Laibl Rogers; Scott W Roberts; George H McCracken; George D Wendel; Jeanne S Sheffield
Journal:  Am J Obstet Gynecol       Date:  2011-03-09       Impact factor: 8.661

7.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

8.  In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Authors:  Katrina Sleeman; Vasiliy P Mishin; Varough M Deyde; Yousuke Furuta; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 9.  Use of oseltamivir in children.

Authors:  Blake Jamieson; Rini Jain; Bruce Carleton; Ran D Goldman
Journal:  Can Fam Physician       Date:  2009-12       Impact factor: 3.275

10.  Population pharmacokinetics of peramivir in healthy volunteers and influenza patients.

Authors:  Yumiko Matsuo; Toru Ishibashi; Alan S Hollister; Toshihiro Wajima
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.